Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2007 1
2010 2
2011 1
2012 3
2013 1
2014 1
2015 1
2016 4
2017 4
2018 4
2019 4
2020 3
2021 11
2022 8
2023 11
2024 40
2025 93
2026 69

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

240 results

Results by year

Filters applied: . Clear all
Page 1
Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism.
Nunn E, Jaiswal N, Gavin M, Uehara K, Stefkovich M, Drareni K, Calhoun R, Lee M, Holman CD, Baur JA, Seale P, Titchenell PM. Nunn E, et al. Mol Metab. 2024 Feb;80:101880. doi: 10.1016/j.molmet.2024.101880. Epub 2024 Jan 11. Mol Metab. 2024. PMID: 38218536 Free PMC article.
OBJECTIVE: Glucagon-like peptide 1 (GLP-1) receptor agonists reduce food intake, producing remarkable weight loss in overweight and obese individuals. While much of this weight loss is fat mass, there is …
OBJECTIVE: Glucagon-like peptide 1 (GLP-1) receptor agonists reduce food intake, producing remarka …
Is Weight Loss-Induced Muscle Mass Loss Clinically Relevant?
Conte C, Hall KD, Klein S. Conte C, et al. JAMA. 2024 Jul 2;332(1):9-10. doi: 10.1001/jama.2024.6586. JAMA. 2024. PMID: 38829659
This Viewpoint explores the effects of weight loss achieved through GLP-1-based antiobesity medications on weight regain, fat-free mass, and skeletal muscle mass in people with obesity....
This Viewpoint explores the effects of weight loss achieved through GLP-1-based antiobesity medications on we …
Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?
Linge J, Birkenfeld AL, Neeland IJ. Linge J, et al. Circulation. 2024 Oct 15;150(16):1288-1298. doi: 10.1161/CIRCULATIONAHA.124.067676. Epub 2024 Oct 14. Circulation. 2024. PMID: 39401279 Review.
Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and combination therapies is approaching magnitudes achieved with surgery. ...This primer aims to address wh …
Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor ago …
Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies.
Neeland IJ, Linge J, Birkenfeld AL. Neeland IJ, et al. Diabetes Obes Metab. 2024 Sep;26 Suppl 4:16-27. doi: 10.1111/dom.15728. Epub 2024 Jun 27. Diabetes Obes Metab. 2024. PMID: 38937282 Free article. Review.
Weight loss induced by glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucagon-like peptide-1 receptor (GLP-1R)/glucose-dependent insulinotropic polypeptide receptor agonists is coming closer to …
Weight loss induced by glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucagon …
Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society.
Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S, Bonnet J, Butsch WS, Christensen S, Gianos E, Gulati M, Gupta A, Horn D, Kane RM, Saluja J, Sannidhi D, Stanford FC, Callahan EA. Mozaffarian D, et al. Obesity (Silver Spring). 2025 Aug;33(8):1475-1503. doi: 10.1002/oby.24336. Epub 2025 May 30. Obesity (Silver Spring). 2025. PMID: 40445127 Free PMC article.
BACKGROUND: Glucagon-like peptide 1 receptor agonists and combination medications (hereafter collectively referred to as GLP-1s) are shifting the treatment landscape for obesity. ...During GLP-1 use, nutritional and medical management of …
BACKGROUND: Glucagon-like peptide 1 receptor agonists and combination medications (hereafter collectively referr …
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.
Stefanakis K, Kokkorakis M, Mantzoros CS. Stefanakis K, et al. Metabolism. 2024 Dec;161:156057. doi: 10.1016/j.metabol.2024.156057. Epub 2024 Oct 30. Metabolism. 2024. PMID: 39481534 Review.
The myostatin-activin-follistatin-inhibin system, originally implicated in reproductive function and subsequently muscle regulation, appears to be crucial for muscle and bone maintenance during weight loss. ...Novel compounds in the pipeline, such as B …
The myostatin-activin-follistatin-inhibin system, originally implicated in reproductive function and subsequently muscle regulation, …
GLP-1-based therapies for diabetes, obesity and beyond.
Drucker DJ. Drucker DJ. Nat Rev Drug Discov. 2025 Aug;24(8):631-650. doi: 10.1038/s41573-025-01183-8. Epub 2025 Apr 25. Nat Rev Drug Discov. 2025. PMID: 40281304 Review.
Glucagon-like peptide 1 (GLP-1)-based therapies, such as semaglutide and tirzepatide, represent highly effective treatment options for people with type 2 diabetes and obesity, enabling effective control of glucose and weight los …
Glucagon-like peptide 1 (GLP-1)-based therapies, such as semaglutide and tirzepatide, represent hi …
Sarcopenic obesity and weight loss-induced muscle mass loss.
Caturano A, Amaro A, Berra CC, Conte C. Caturano A, et al. Curr Opin Clin Nutr Metab Care. 2025 Jul 1;28(4):339-350. doi: 10.1097/MCO.0000000000001131. Epub 2025 Apr 29. Curr Opin Clin Nutr Metab Care. 2025. PMID: 40296814 Free PMC article. Review.
PURPOSE OF REVIEW: Sarcopenic obesity is a clinical condition characterized by the coexistence of excess adiposity and impaired muscle function, associated with heightened cardiometabolic risk and frailty. The emergence of new incretin-based obesity management medications …
PURPOSE OF REVIEW: Sarcopenic obesity is a clinical condition characterized by the coexistence of excess adiposity and impaired muscle …
Glucagon-like peptide-1 receptor agonists and muscle mass effects.
Ceasovschih A, Asaftei A, Lupo MG, Kotlyarov S, Bartušková H, Balta A, Sorodoc V, Sorodoc L, Banach M. Ceasovschih A, et al. Pharmacol Res. 2025 Oct;220:107927. doi: 10.1016/j.phrs.2025.107927. Epub 2025 Aug 24. Pharmacol Res. 2025. PMID: 40858197 Free article. Review.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of obesity, demonstrating significant efficacy in inducing weight loss and improving metabolic parameters. ...This review critically exami …
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of obesity, …
Muscle loss and GLP-1R agonists use.
Rossi G, Bucciarelli L, Mananguite CL, Giovarelli M, Fiorina P. Rossi G, et al. Acta Diabetol. 2026 Feb;63(2):333-342. doi: 10.1007/s00592-025-02611-2. Epub 2025 Nov 7. Acta Diabetol. 2026. PMID: 41201615 Free PMC article. Review.
Loss of muscle mass and strength not only impairs mobility and quality of life, but also worsens insulin resistance, accelerates cardiometabolic decline and increases mortality risk. The convergence of chronic inflammation, mitochondrial dysfunction and alter …
Loss of muscle mass and strength not only impairs mobility and quality of life, but also worsens insulin resistance, ac …
240 results